Antioxidant, α-glucosidase inhibitory and in vitro antitumor activities of coumarin-benzothiazole hybrids

Coumarin-benzothiazole hybrids are antitumor agents based on their antioxidant and a-glucosidase inhibitory activities. Compounds 5a-c were selected by National Cancer Institute (NCI), USA, to be screened for antitumor activity at a single dose (10 mu m) against a panel of 60 cancer cell lines. The most active compound 5c was further screened at a five-dose level by NCI. Compound 5c displays half maximal growth inhibition (GI(50)) values of 0.24 and 0.33 mu m against central nervous system (CNS) cancer-(SNB-75) and ovarian cancer (OVCAR-4) cell lines, respectively. Compounds 5a-c were also screened for their antioxidant and alpha-glucosidase inhibitory activities.